Chemicals
Showing 34351–34500 of 41137 results
-
Rifabutin is a broad-spectrum rifamycin antibiotic that has applications against tuberculosis, H. pylori, M. avium complex, Chlamydia, and other bacteria.{27027,26320,27023}
Brand:CaymanSKU:-Out of stock
Rifabutin is a broad-spectrum rifamycin antibiotic that has applications against tuberculosis, H. pylori, M. avium complex, Chlamydia, and other bacteria.{27027,26320,27023}
Brand:CaymanSKU:-Out of stock
Rifabutin is a broad-spectrum rifamycin antibiotic that has applications against tuberculosis, H. pylori, M. avium complex, Chlamydia, and other bacteria.{27027,26320,27023}
Brand:CaymanSKU:-Out of stock
Rifampicin is a rifamycin antibiotic and inhibitor of bacterial RNA polymerase (IC50 = 0.01 μg/ml for the E. coli enzyme).{23992} It inhibits the growth of M. tuberculosis H37Rv in mouse peritoneal macrophages (MIC = 0.8 μg/ml) as well as clinical isolates of various species of Staphylococcus, Streptococcus, Haemophilus, and Neisseria (MICs = 0.009-1.4 μg/ml).{40531,32022} Rifampicin increases survival in a mouse model of tuberculosis infection.{32022} It is also an agonist of the human pregnane X receptor (PXR; EC50 = ~2 μM).{23996} Formulations containing rifampicin have been used in the treatment of tuberculosis and meningococcal carriers.
Brand:CaymanSKU:- Rifampicin is a rifamycin antibiotic and inhibitor of bacterial RNA polymerase (IC50 = 0.01 μg/ml for the E. coli enzyme).{23992} It inhibits the growth of M. tuberculosis H37Rv in mouse peritoneal macrophages (MIC = 0.8 μg/ml) as well as clinical isolates of various species of Staphylococcus, Streptococcus, Haemophilus, and Neisseria (MICs = 0.009-1.4 μg/ml).{40531,32022} Rifampicin increases survival in a mouse model of tuberculosis infection.{32022} It is also an agonist of the human pregnane X receptor (PXR; EC50 = ~2 μM).{23996} Formulations containing rifampicin have been used in the treatment of tuberculosis and meningococcal carriers.
Brand:CaymanSKU:- Rifampicin is a rifamycin antibiotic and inhibitor of bacterial RNA polymerase (IC50 = 0.01 μg/ml for the E. coli enzyme).{23992} It inhibits the growth of M. tuberculosis H37Rv in mouse peritoneal macrophages (MIC = 0.8 μg/ml) as well as clinical isolates of various species of Staphylococcus, Streptococcus, Haemophilus, and Neisseria (MICs = 0.009-1.4 μg/ml).{40531,32022} Rifampicin increases survival in a mouse model of tuberculosis infection.{32022} It is also an agonist of the human pregnane X receptor (PXR; EC50 = ~2 μM).{23996} Formulations containing rifampicin have been used in the treatment of tuberculosis and meningococcal carriers.
Brand:CaymanSKU:- Rifampicin is a rifamycin antibiotic and inhibitor of bacterial RNA polymerase (IC50 = 0.01 μg/ml for the E. coli enzyme).{23992} It inhibits the growth of M. tuberculosis H37Rv in mouse peritoneal macrophages (MIC = 0.8 μg/ml) as well as clinical isolates of various species of Staphylococcus, Streptococcus, Haemophilus, and Neisseria (MICs = 0.009-1.4 μg/ml).{40531,32022} Rifampicin increases survival in a mouse model of tuberculosis infection.{32022} It is also an agonist of the human pregnane X receptor (PXR; EC50 = ~2 μM).{23996} Formulations containing rifampicin have been used in the treatment of tuberculosis and meningococcal carriers.
Brand:CaymanSKU:-
Rifampicin-d3 is intended for use as an internal standard for the quantification of rifampicin (Item No. 14423) by GC- or LC-MS. Rifampicin is a rifamycin antibiotic and inhibitor of bacterial RNA polymerase (IC50 = 0.01 μg/ml for the E. coli enzyme).{23992} It inhibits the growth of M. tuberculosis H37Rv in mouse peritoneal macrophages (MIC = 0.8 μg/ml) as well as clinical isolates of various species of Staphylococcus, Streptococcus, Haemophilus, and Neisseria (MICs = 0.009-1.4 μg/ml).{40531,32022} Rifampicin increases survival in a mouse model of tuberculosis infection.{32022} It is also an agonist of the human pregnane X receptor (PXR; EC50 = ~2 μM).{23996} Formulations containing rifampicin have been used in the treatment of tuberculosis and meningococcal carriers.
Brand:CaymanSKU:27848 - 500 µgAvailable on backorder
Rifapentine is a long-lasting rifamycin antibiotic that inhibits DNA-dependent RNA polymerases and is effective against Mycobacterium species, including M. tuberculosis, as well as experimental infections caused by S. aureus, S. pyogenes group A, S. pneumoniae, and K. pneumoniae.{32022,32023}
Brand:CaymanSKU:20307 -Available on backorder
Rifapentine is a long-lasting rifamycin antibiotic that inhibits DNA-dependent RNA polymerases and is effective against Mycobacterium species, including M. tuberculosis, as well as experimental infections caused by S. aureus, S. pyogenes group A, S. pneumoniae, and K. pneumoniae.{32022,32023}
Brand:CaymanSKU:20307 -Available on backorder
Rifapentine is a long-lasting rifamycin antibiotic that inhibits DNA-dependent RNA polymerases and is effective against Mycobacterium species, including M. tuberculosis, as well as experimental infections caused by S. aureus, S. pyogenes group A, S. pneumoniae, and K. pneumoniae.{32022,32023}
Brand:CaymanSKU:20307 -Available on backorder
Rifapentine is a long-lasting rifamycin antibiotic that inhibits DNA-dependent RNA polymerases and is effective against Mycobacterium species, including M. tuberculosis, as well as experimental infections caused by S. aureus, S. pyogenes group A, S. pneumoniae, and K. pneumoniae.{32022,32023}
Brand:CaymanSKU:20307 -Available on backorder
Rifaximin is an antibiotic derived from rifamycin SV (Item No. 21441) that inhibits the growth of a variety of Gram-positive and Gram-negative bacteria in vitro, including Staphylococcus, Streptococcus, Enterococcus, H. influenzae, and N. gonorrhoeae (MIC50s = ≤0.015, 50 = ~20 μM) that reduces colonic damage, rectal bleeding, and diarrhea in PXR-humanized, but not wild-type or Pxr-null, mice with inflammatory bowel disease (IBD) induced by dextran sulfate sodium (DSS; Item No. 23250).{42471,42472} Rifaximin exhibits minimal intestinal absorption after oral administration and is, therefore, effective in eliminating bacteria in the gastrointestinal system.{26322,26320} Formulations containing rifaximin have been used in the treatment travelers’ diarrhea caused by noninvasive E. coli, irritable bowel syndrome with diarrhea (IBS-D), and to reduce the risk of recurrence of overt hepatic encephalopathy.
Brand:CaymanSKU:- Rifaximin is an antibiotic derived from rifamycin SV (Item No. 21441) that inhibits the growth of a variety of Gram-positive and Gram-negative bacteria in vitro, including Staphylococcus, Streptococcus, Enterococcus, H. influenzae, and N. gonorrhoeae (MIC50s = ≤0.015, 50 = ~20 μM) that reduces colonic damage, rectal bleeding, and diarrhea in PXR-humanized, but not wild-type or Pxr-null, mice with inflammatory bowel disease (IBD) induced by dextran sulfate sodium (DSS; Item No. 23250).{42471,42472} Rifaximin exhibits minimal intestinal absorption after oral administration and is, therefore, effective in eliminating bacteria in the gastrointestinal system.{26322,26320} Formulations containing rifaximin have been used in the treatment travelers’ diarrhea caused by noninvasive E. coli, irritable bowel syndrome with diarrhea (IBS-D), and to reduce the risk of recurrence of overt hepatic encephalopathy.
Brand:CaymanSKU:- Rifaximin is an antibiotic derived from rifamycin SV (Item No. 21441) that inhibits the growth of a variety of Gram-positive and Gram-negative bacteria in vitro, including Staphylococcus, Streptococcus, Enterococcus, H. influenzae, and N. gonorrhoeae (MIC50s = ≤0.015, 50 = ~20 μM) that reduces colonic damage, rectal bleeding, and diarrhea in PXR-humanized, but not wild-type or Pxr-null, mice with inflammatory bowel disease (IBD) induced by dextran sulfate sodium (DSS; Item No. 23250).{42471,42472} Rifaximin exhibits minimal intestinal absorption after oral administration and is, therefore, effective in eliminating bacteria in the gastrointestinal system.{26322,26320} Formulations containing rifaximin have been used in the treatment travelers’ diarrhea caused by noninvasive E. coli, irritable bowel syndrome with diarrhea (IBS-D), and to reduce the risk of recurrence of overt hepatic encephalopathy.
Brand:CaymanSKU:- Rifaximin is an antibiotic derived from rifamycin SV (Item No. 21441) that inhibits the growth of a variety of Gram-positive and Gram-negative bacteria in vitro, including Staphylococcus, Streptococcus, Enterococcus, H. influenzae, and N. gonorrhoeae (MIC50s = ≤0.015, 50 = ~20 μM) that reduces colonic damage, rectal bleeding, and diarrhea in PXR-humanized, but not wild-type or Pxr-null, mice with inflammatory bowel disease (IBD) induced by dextran sulfate sodium (DSS; Item No. 23250).{42471,42472} Rifaximin exhibits minimal intestinal absorption after oral administration and is, therefore, effective in eliminating bacteria in the gastrointestinal system.{26322,26320} Formulations containing rifaximin have been used in the treatment travelers’ diarrhea caused by noninvasive E. coli, irritable bowel syndrome with diarrhea (IBS-D), and to reduce the risk of recurrence of overt hepatic encephalopathy.
Brand:CaymanSKU:-
Rifaximin-d6 is intended for use as an internal standard for the quantification of rifaximin (Item No. 16131) by GC- or LC-MS. Rifaximin is an antibiotic derived from rifamycin SV (Item No. 21441) that inhibits the growth of a variety of Gram-positive and Gram-negative bacteria in vitro, including Staphylococcus, Streptococcus, Enterococcus, H. influenzae, and N. gonorrhoeae (MIC50s = ≤0.015, 50 = ~20 μM) that reduces colonic damage, rectal bleeding, and diarrhea in PXR-humanized, but not wild-type or Pxr-null, mice with inflammatory bowel disease (IBD) induced by dextran sulfate sodium (DSS; Item No. 23250).{42471,42472} Rifaximin exhibits minimal intestinal absorption after oral administration and is, therefore, effective in eliminating bacteria in the gastrointestinal system.{26322,26320} Formulations containing rifaximin have been used in the treatment of traveler’s diarrhea caused by noninvasive E. coli, irritable bowel syndrome with diarrhea (IBS-D), and to reduce the risk of recurrence of overt hepatic encephalopathy.
Brand:CaymanSKU:26101 - 1 mgAvailable on backorder
Rifaximin-d6 is intended for use as an internal standard for the quantification of rifaximin (Item No. 16131) by GC- or LC-MS. Rifaximin is an antibiotic derived from rifamycin SV (Item No. 21441) that inhibits the growth of a variety of Gram-positive and Gram-negative bacteria in vitro, including Staphylococcus, Streptococcus, Enterococcus, H. influenzae, and N. gonorrhoeae (MIC50s = ≤0.015, 50 = ~20 μM) that reduces colonic damage, rectal bleeding, and diarrhea in PXR-humanized, but not wild-type or Pxr-null, mice with inflammatory bowel disease (IBD) induced by dextran sulfate sodium (DSS; Item No. 23250).{42471,42472} Rifaximin exhibits minimal intestinal absorption after oral administration and is, therefore, effective in eliminating bacteria in the gastrointestinal system.{26322,26320} Formulations containing rifaximin have been used in the treatment of traveler’s diarrhea caused by noninvasive E. coli, irritable bowel syndrome with diarrhea (IBS-D), and to reduce the risk of recurrence of overt hepatic encephalopathy.
Brand:CaymanSKU:26101 - 500 µgAvailable on backorder
Rilmenidine is a centrally acting antihypertensive agent that has been shown to lower arterial pressure in various animal models by inhibiting the tonic activity of sympathoexcitatory neurons in the rostral ventrolateral medulla.{25847} Rilmenidine targets the nonadrenergic imidazoline-binding site I1 receptor with a Ki value of 7.1 nM and demonstrates weaker affinity for the I2 receptor with a Ki value of 5.2 µM.{25846,30142} It can also act as an agonist of α2-adrenergic receptors, but demonstrates ~30-fold greater selectivity for I1 receptors compared to α2-adrenergic receptors.{30141} Rilmenidine is reported to induce autophagy as evidenced by a ~350% increase in LC3-II levels in PC12 cells when treated with 1 µM of the I1 agonist.{30143}
Brand:CaymanSKU:-Out of stock
Rilmenidine is a centrally acting antihypertensive agent that has been shown to lower arterial pressure in various animal models by inhibiting the tonic activity of sympathoexcitatory neurons in the rostral ventrolateral medulla.{25847} Rilmenidine targets the nonadrenergic imidazoline-binding site I1 receptor with a Ki value of 7.1 nM and demonstrates weaker affinity for the I2 receptor with a Ki value of 5.2 µM.{25846,30142} It can also act as an agonist of α2-adrenergic receptors, but demonstrates ~30-fold greater selectivity for I1 receptors compared to α2-adrenergic receptors.{30141} Rilmenidine is reported to induce autophagy as evidenced by a ~350% increase in LC3-II levels in PC12 cells when treated with 1 µM of the I1 agonist.{30143}
Brand:CaymanSKU:-Out of stock
Rilmenidine is a centrally acting antihypertensive agent that has been shown to lower arterial pressure in various animal models by inhibiting the tonic activity of sympathoexcitatory neurons in the rostral ventrolateral medulla.{25847} Rilmenidine targets the nonadrenergic imidazoline-binding site I1 receptor with a Ki value of 7.1 nM and demonstrates weaker affinity for the I2 receptor with a Ki value of 5.2 µM.{25846,30142} It can also act as an agonist of α2-adrenergic receptors, but demonstrates ~30-fold greater selectivity for I1 receptors compared to α2-adrenergic receptors.{30141} Rilmenidine is reported to induce autophagy as evidenced by a ~350% increase in LC3-II levels in PC12 cells when treated with 1 µM of the I1 agonist.{30143}
Brand:CaymanSKU:-Out of stock
Rilmenidine is a centrally acting antihypertensive agent that has been shown to lower arterial pressure in various animal models by inhibiting the tonic activity of sympathoexcitatory neurons in the rostral ventrolateral medulla.{25847} Rilmenidine targets the nonadrenergic imidazoline-binding site I1 receptor with a Ki value of 7.1 nM and demonstrates weaker affinity for the I2 receptor with a Ki value of 5.2 µM.{25846,30142} It can also act as an agonist of α2-adrenergic receptors, but demonstrates ~30-fold greater selectivity for I1 receptors compared to α2-adrenergic receptors.{30141} Rilmenidine is reported to induce autophagy as evidenced by a ~350% increase in LC3-II levels in PC12 cells when treated with 1 µM of the I1 agonist.{30143}
Brand:CaymanSKU:-Out of stock
Rilmenidine-d4 is intended for use as an internal standard for the quantification of rilmenidine (Item No. 16988) by GC- or LC-MS. Rilmenidine is an antihypertensive agent.{61133} It binds to imidazole receptors in bovine rostral ventrolateral medulla homogenates (Ki = 6.1 nM), as well as α2-adrenergic receptors in bovine prefrontal cortex homogenates (Ki = 87 nM). Rilmenidine induces hypotension and bradycardia in anesthetized rats (ED50s = 0.25 and 0.35 mg/kg, respectively). It also reduces mean arterial pressure and renal sympathetic nerve activity in a rabbit model of renal hypertension induced by a renal artery clip when administered at a dose of 2.5 mg/kg.{61134} Rilmenidine (1 µM) increases levels of LC3-II, a marker of autophagy, in PC12 cells.{30143} Formulations containing rilmenidine have been used in the treatment of hypertension.
Brand:CaymanSKU:31691 - 1 mgAvailable on backorder
Rilmenidine-d4 is intended for use as an internal standard for the quantification of rilmenidine (Item No. 16988) by GC- or LC-MS. Rilmenidine is an antihypertensive agent.{61133} It binds to imidazole receptors in bovine rostral ventrolateral medulla homogenates (Ki = 6.1 nM), as well as α2-adrenergic receptors in bovine prefrontal cortex homogenates (Ki = 87 nM). Rilmenidine induces hypotension and bradycardia in anesthetized rats (ED50s = 0.25 and 0.35 mg/kg, respectively). It also reduces mean arterial pressure and renal sympathetic nerve activity in a rabbit model of renal hypertension induced by a renal artery clip when administered at a dose of 2.5 mg/kg.{61134} Rilmenidine (1 µM) increases levels of LC3-II, a marker of autophagy, in PC12 cells.{30143} Formulations containing rilmenidine have been used in the treatment of hypertension.
Brand:CaymanSKU:31691 - 500 µgAvailable on backorder
Rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that inhibits growth of wild-type HIV with an EC50 value of 0.51 nM.{35241} It is active against NNRTI-resistant HIV strains with EC50 values less than 1 nM for L100I, K103N, V106A, G190A, and G190S mutants in vitro. Rilpivirine also reduces growth of greater than 80% of 1,500 NNRTI-resistant clinical isolates (EC50s = In vivo, rilpivirine, when used in combination with cabotegravir, lamivudine (Item No. 18514), and abcavir, reduces the plasma viral titer in HIV-1 infected humanized mice.{35242}
Brand:CaymanSKU:21559 -Out of stock
Rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that inhibits growth of wild-type HIV with an EC50 value of 0.51 nM.{35241} It is active against NNRTI-resistant HIV strains with EC50 values less than 1 nM for L100I, K103N, V106A, G190A, and G190S mutants in vitro. Rilpivirine also reduces growth of greater than 80% of 1,500 NNRTI-resistant clinical isolates (EC50s = In vivo, rilpivirine, when used in combination with cabotegravir, lamivudine (Item No. 18514), and abcavir, reduces the plasma viral titer in HIV-1 infected humanized mice.{35242}
Brand:CaymanSKU:21559 -Out of stock
Rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that inhibits growth of wild-type HIV with an EC50 value of 0.51 nM.{35241} It is active against NNRTI-resistant HIV strains with EC50 values less than 1 nM for L100I, K103N, V106A, G190A, and G190S mutants in vitro. Rilpivirine also reduces growth of greater than 80% of 1,500 NNRTI-resistant clinical isolates (EC50s = In vivo, rilpivirine, when used in combination with cabotegravir, lamivudine (Item No. 18514), and abcavir, reduces the plasma viral titer in HIV-1 infected humanized mice.{35242}
Brand:CaymanSKU:21559 -Out of stock
Rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that inhibits growth of wild-type HIV with an EC50 value of 0.51 nM.{35241} It is active against NNRTI-resistant HIV strains with EC50 values less than 1 nM for L100I, K103N, V106A, G190A, and G190S mutants in vitro. Rilpivirine also reduces growth of greater than 80% of 1,500 NNRTI-resistant clinical isolates (EC50s = In vivo, rilpivirine, when used in combination with cabotegravir, lamivudine (Item No. 18514), and abcavir, reduces the plasma viral titer in HIV-1 infected humanized mice.{35242}
Brand:CaymanSKU:21559 -Out of stock
Riluzole is a benzothiazole derivative with anti-excitotoxic effects that acts by blocking the presynaptic release of glutamate, indirectly antagonizing glutamate receptors, and inactivating neuronal voltage-gated Na+ channels (ED50 = 2.3 μM).{22851} Riluzole suppresses glutamate-induced seizures in rats at an ED50 value of 3.2 mg/kg and displays neuroprotective effects in hypoxic animals at an ED50 value of 4 mg/kg.{22851} Formulations containing riluzole have been explored as therapeutics for slowing disease progression of amyotrophic lateral sclerosis.{22851}
Brand:CaymanSKU:- Riluzole is a benzothiazole derivative with anti-excitotoxic effects that acts by blocking the presynaptic release of glutamate, indirectly antagonizing glutamate receptors, and inactivating neuronal voltage-gated Na+ channels (ED50 = 2.3 μM).{22851} Riluzole suppresses glutamate-induced seizures in rats at an ED50 value of 3.2 mg/kg and displays neuroprotective effects in hypoxic animals at an ED50 value of 4 mg/kg.{22851} Formulations containing riluzole have been explored as therapeutics for slowing disease progression of amyotrophic lateral sclerosis.{22851}
Brand:CaymanSKU:-
Riluzole-13C,15N2 is intended for use as an internal standard for the quantification of riluzole (Item No. 14577) by GC- or LC-MS. Riluzole is a benzothiazole derivative with anti-excitotoxic effects that acts by blocking the presynaptic release of glutamate, indirectly antagonizing glutamate receptors, and inactivating neuronal voltage-gated Na+ channels (ED50 = 2.3 μM).{22851} Riluzole suppresses glutamate-induced seizures in rats at an ED50 value of 3.2 mg/kg and displays neuroprotective effects in hypoxic animals at an ED50 value of 4 mg/kg. Formulations containing riluzole have been explored as therapeutics for slowing disease progression of amyotrophic lateral sclerosis.
Brand:CaymanSKU:25361 - 1 mgAvailable on backorder
Rimantadine is a derivative of amantadine (Item No. 21364) with antiviral activity.{22179} It inhibits recombinant influenza A matrix protein 2 (M2) expressed in X. laevis oocytes (IC50 = 10.8 µM) and recombinant hepatitis C virus (HCV) p7 protein expressed in HEK293 cells (IC50s = 0.7, 24, 1.6, and 3.0 nM for HCV genotypes 1a, 2a, 3a, and 4a, respectively).{43207,43208} Rimantadine inhibits cytotoxicity induced by the influenza A strains A/PR/8/34 (H1N1) and A/HK/7/87 (H3N2), but not the influenza B strain B/HK/72, in MDCK cells (EC50s = 18, 0.62, and >500 µM, respectively).{42218} It increases the survival rate of mice infected with the influenza A strain A2/Jap/305 from 20 to 90% when administered at a dose of 24 mg/kg two hours post-infection, with the survival rate decreasing when rimantadine is administered at longer timepoints following infection.{43209} It also has trypanocidal activity against bloodstream forms of T. brucei in vitro (IC50 = 1.26 µg/ml).{43210} Formulations containing rimantadine have been used in the prophylaxis and treatment of influenza A.
Brand:CaymanSKU:23838 - 100 mgAvailable on backorder
Rimantadine is a derivative of amantadine (Item No. 21364) with antiviral activity.{22179} It inhibits recombinant influenza A matrix protein 2 (M2) expressed in X. laevis oocytes (IC50 = 10.8 µM) and recombinant hepatitis C virus (HCV) p7 protein expressed in HEK293 cells (IC50s = 0.7, 24, 1.6, and 3.0 nM for HCV genotypes 1a, 2a, 3a, and 4a, respectively).{43207,43208} Rimantadine inhibits cytotoxicity induced by the influenza A strains A/PR/8/34 (H1N1) and A/HK/7/87 (H3N2), but not the influenza B strain B/HK/72, in MDCK cells (EC50s = 18, 0.62, and >500 µM, respectively).{42218} It increases the survival rate of mice infected with the influenza A strain A2/Jap/305 from 20 to 90% when administered at a dose of 24 mg/kg two hours post-infection, with the survival rate decreasing when rimantadine is administered at longer timepoints following infection.{43209} It also has trypanocidal activity against bloodstream forms of T. brucei in vitro (IC50 = 1.26 µg/ml).{43210} Formulations containing rimantadine have been used in the prophylaxis and treatment of influenza A.
Brand:CaymanSKU:23838 - 25 mgAvailable on backorder
Rimantadine is a derivative of amantadine (Item No. 21364) with antiviral activity.{22179} It inhibits recombinant influenza A matrix protein 2 (M2) expressed in X. laevis oocytes (IC50 = 10.8 µM) and recombinant hepatitis C virus (HCV) p7 protein expressed in HEK293 cells (IC50s = 0.7, 24, 1.6, and 3.0 nM for HCV genotypes 1a, 2a, 3a, and 4a, respectively).{43207,43208} Rimantadine inhibits cytotoxicity induced by the influenza A strains A/PR/8/34 (H1N1) and A/HK/7/87 (H3N2), but not the influenza B strain B/HK/72, in MDCK cells (EC50s = 18, 0.62, and >500 µM, respectively).{42218} It increases the survival rate of mice infected with the influenza A strain A2/Jap/305 from 20 to 90% when administered at a dose of 24 mg/kg two hours post-infection, with the survival rate decreasing when rimantadine is administered at longer timepoints following infection.{43209} It also has trypanocidal activity against bloodstream forms of T. brucei in vitro (IC50 = 1.26 µg/ml).{43210} Formulations containing rimantadine have been used in the prophylaxis and treatment of influenza A.
Brand:CaymanSKU:23838 - 250 mgAvailable on backorder
Rimantadine is a derivative of amantadine (Item No. 21364) with antiviral activity.{22179} It inhibits recombinant influenza A matrix protein 2 (M2) expressed in X. laevis oocytes (IC50 = 10.8 µM) and recombinant hepatitis C virus (HCV) p7 protein expressed in HEK293 cells (IC50s = 0.7, 24, 1.6, and 3.0 nM for HCV genotypes 1a, 2a, 3a, and 4a, respectively).{43207,43208} Rimantadine inhibits cytotoxicity induced by the influenza A strains A/PR/8/34 (H1N1) and A/HK/7/87 (H3N2), but not the influenza B strain B/HK/72, in MDCK cells (EC50s = 18, 0.62, and >500 µM, respectively).{42218} It increases the survival rate of mice infected with the influenza A strain A2/Jap/305 from 20 to 90% when administered at a dose of 24 mg/kg two hours post-infection, with the survival rate decreasing when rimantadine is administered at longer timepoints following infection.{43209} It also has trypanocidal activity against bloodstream forms of T. brucei in vitro (IC50 = 1.26 µg/ml).{43210} Formulations containing rimantadine have been used in the prophylaxis and treatment of influenza A.
Brand:CaymanSKU:23838 - 50 mgAvailable on backorder
Rimegepant is an orally bioavailable antagonist of the calcitonin gene-related peptide (CGRP) receptor (Ki = 0.027 nM).{47524} It inhibits cAMP production stimulated by α-CGRP (Item No. 24405) in SK-N-MC human neuroblastoma cells (IC50 = 0.14 nM). Rimegepant (7 mg/kg, s.c.) reduces human α-CGRP-induced increases in facial blood flow, a surrogate for changes in intracranial artery diameter, in anesthetized marmosets.
Brand:CaymanSKU:26338 - 1 mgAvailable on backorder
Rimegepant is an orally bioavailable antagonist of the calcitonin gene-related peptide (CGRP) receptor (Ki = 0.027 nM).{47524} It inhibits cAMP production stimulated by α-CGRP (Item No. 24405) in SK-N-MC human neuroblastoma cells (IC50 = 0.14 nM). Rimegepant (7 mg/kg, s.c.) reduces human α-CGRP-induced increases in facial blood flow, a surrogate for changes in intracranial artery diameter, in anesthetized marmosets.
Brand:CaymanSKU:26338 - 10 mgAvailable on backorder
Rimegepant is an orally bioavailable antagonist of the calcitonin gene-related peptide (CGRP) receptor (Ki = 0.027 nM).{47524} It inhibits cAMP production stimulated by α-CGRP (Item No. 24405) in SK-N-MC human neuroblastoma cells (IC50 = 0.14 nM). Rimegepant (7 mg/kg, s.c.) reduces human α-CGRP-induced increases in facial blood flow, a surrogate for changes in intracranial artery diameter, in anesthetized marmosets.
Brand:CaymanSKU:26338 - 25 mgAvailable on backorder
Rimegepant is an orally bioavailable antagonist of the calcitonin gene-related peptide (CGRP) receptor (Ki = 0.027 nM).{47524} It inhibits cAMP production stimulated by α-CGRP (Item No. 24405) in SK-N-MC human neuroblastoma cells (IC50 = 0.14 nM). Rimegepant (7 mg/kg, s.c.) reduces human α-CGRP-induced increases in facial blood flow, a surrogate for changes in intracranial artery diameter, in anesthetized marmosets.
Brand:CaymanSKU:26338 - 5 mgAvailable on backorder
Rimonabant is a potent and selective cannabinoid (CB) receptor 1 antagonist (Kis = 5.6 and >1,000 nM for CB1 and CB2, respectively).{3133} In rodent models, rimonabant induces lipolysis, reduces hepatomegaly, decreases body weight, and improves dyslipidemia by reducing triglyceride, free fatty acid, and total cholesterol levels and by increasing HDL/LDL ratios.{17168} Rimonabant elicits antiproliferative and immunomodulatory effects (e.g., cell cycle arrest, increased expression of IκB and phosphorylated Akt, and decreased expression of NF-κB, phosphorylated ERK1/2, COX-2, and iNOS) in vitro.{17167}
Brand:CaymanSKU:9000484 - 10 mgAvailable on backorder
Rimonabant is a potent and selective cannabinoid (CB) receptor 1 antagonist (Kis = 5.6 and >1,000 nM for CB1 and CB2, respectively).{3133} In rodent models, rimonabant induces lipolysis, reduces hepatomegaly, decreases body weight, and improves dyslipidemia by reducing triglyceride, free fatty acid, and total cholesterol levels and by increasing HDL/LDL ratios.{17168} Rimonabant elicits antiproliferative and immunomodulatory effects (e.g., cell cycle arrest, increased expression of IκB and phosphorylated Akt, and decreased expression of NF-κB, phosphorylated ERK1/2, COX-2, and iNOS) in vitro.{17167}
Brand:CaymanSKU:9000484 - 25 mgAvailable on backorder
Rimonabant is a potent and selective cannabinoid (CB) receptor 1 antagonist (Kis = 5.6 and >1,000 nM for CB1 and CB2, respectively).{3133} In rodent models, rimonabant induces lipolysis, reduces hepatomegaly, decreases body weight, and improves dyslipidemia by reducing triglyceride, free fatty acid, and total cholesterol levels and by increasing HDL/LDL ratios.{17168} Rimonabant elicits antiproliferative and immunomodulatory effects (e.g., cell cycle arrest, increased expression of IκB and phosphorylated Akt, and decreased expression of NF-κB, phosphorylated ERK1/2, COX-2, and iNOS) in vitro.{17167}
Brand:CaymanSKU:9000484 - 5 mgAvailable on backorder
Rimonabant is a potent and selective cannabinoid (CB) receptor 1 antagonist (Kis = 5.6 and >1,000 nM for CB1 and CB2, respectively).{3133} In rodent models, rimonabant induces lipolysis, reduces hepatomegaly, decreases body weight, and improves dyslipidemia by reducing triglyceride, free fatty acid, and total cholesterol levels and by increasing HDL/LDL ratios.{17168} Rimonabant elicits antiproliferative and immunomodulatory effects (e.g., cell cycle arrest, increased expression of IκB and phosphorylated Akt, and decreased expression of NF-κB, phosphorylated ERK1/2, COX-2, and iNOS) in vitro.{17167}
Brand:CaymanSKU:9000484 - 50 mgAvailable on backorder
Rimonabant-d10 contains 10 deuterium atoms at the 2, 2’, 3, 3’, 4, 4’, 5, 5’, 6, and 6’ positions. It is intended for use as an internal standard for the quantification of rimonabant (Item No. 9000484) by GC- or LC-MS. Rimonabant, also known as SR141716, was the first selective central cannabinoid (CB1) receptor inverse agonist (Ki = 1.8 nM) to be developed as an appetite suppressant and anti-obesity drug.{3133} It is widely used as a tool to investigate CB receptor properties and the mechanisms by which CB agonists exert their pharmacological effects.
Brand:CaymanSKU:9001821 - 1 mgAvailable on backorder
Rimonabant-d10 contains 10 deuterium atoms at the 2, 2’, 3, 3’, 4, 4’, 5, 5’, 6, and 6’ positions. It is intended for use as an internal standard for the quantification of rimonabant (Item No. 9000484) by GC- or LC-MS. Rimonabant, also known as SR141716, was the first selective central cannabinoid (CB1) receptor inverse agonist (Ki = 1.8 nM) to be developed as an appetite suppressant and anti-obesity drug.{3133} It is widely used as a tool to investigate CB receptor properties and the mechanisms by which CB agonists exert their pharmacological effects.
Brand:CaymanSKU:9001821 - 500 µgAvailable on backorder
Riociguat is a stimulator of soluble guanylate cyclase (sGC).{36864},{26751} It stimulates recombinant sGC in a concentration-dependent manner in vitro by up to 73-fold when used at a concentration of 100 μM or by up to 112-fold when used in combination with the nitric oxide (NO) donor DEA NONOate (Item No. 82100).{36864} It has no effect on phosphodiesterases PDE1-9 and PDE11 when used at concentrations up to 3 μM. Riociguat (1 and 10 mg/kg) reduces pulmonary and systemic arterial pressure in a rabbit model of acute pulmonary arterial hypertension (PAH) induced by U-46619 (Item No. 16450). It also inhibits increases in right ventricular systolic pressure, right heart hypertrophy, and pulmonary artery muscularization in hypoxia-induced mouse and monocrotaline-injected rat models of chronic PAH when administered at a dose of 10 mg/kg. Formulations containing riociguat have been used in the treatment of chronic thromboembolic pulmonary hypertension (CTEPH) and PAH.
Brand:CaymanSKU:9000554 - 10 mgAvailable on backorder
Riociguat is a stimulator of soluble guanylate cyclase (sGC).{36864},{26751} It stimulates recombinant sGC in a concentration-dependent manner in vitro by up to 73-fold when used at a concentration of 100 μM or by up to 112-fold when used in combination with the nitric oxide (NO) donor DEA NONOate (Item No. 82100).{36864} It has no effect on phosphodiesterases PDE1-9 and PDE11 when used at concentrations up to 3 μM. Riociguat (1 and 10 mg/kg) reduces pulmonary and systemic arterial pressure in a rabbit model of acute pulmonary arterial hypertension (PAH) induced by U-46619 (Item No. 16450). It also inhibits increases in right ventricular systolic pressure, right heart hypertrophy, and pulmonary artery muscularization in hypoxia-induced mouse and monocrotaline-injected rat models of chronic PAH when administered at a dose of 10 mg/kg. Formulations containing riociguat have been used in the treatment of chronic thromboembolic pulmonary hypertension (CTEPH) and PAH.
Brand:CaymanSKU:9000554 - 25 mgAvailable on backorder
Riociguat is a stimulator of soluble guanylate cyclase (sGC).{36864},{26751} It stimulates recombinant sGC in a concentration-dependent manner in vitro by up to 73-fold when used at a concentration of 100 μM or by up to 112-fold when used in combination with the nitric oxide (NO) donor DEA NONOate (Item No. 82100).{36864} It has no effect on phosphodiesterases PDE1-9 and PDE11 when used at concentrations up to 3 μM. Riociguat (1 and 10 mg/kg) reduces pulmonary and systemic arterial pressure in a rabbit model of acute pulmonary arterial hypertension (PAH) induced by U-46619 (Item No. 16450). It also inhibits increases in right ventricular systolic pressure, right heart hypertrophy, and pulmonary artery muscularization in hypoxia-induced mouse and monocrotaline-injected rat models of chronic PAH when administered at a dose of 10 mg/kg. Formulations containing riociguat have been used in the treatment of chronic thromboembolic pulmonary hypertension (CTEPH) and PAH.
Brand:CaymanSKU:9000554 - 5 mgAvailable on backorder
Riociguat is a stimulator of soluble guanylate cyclase (sGC).{36864},{26751} It stimulates recombinant sGC in a concentration-dependent manner in vitro by up to 73-fold when used at a concentration of 100 μM or by up to 112-fold when used in combination with the nitric oxide (NO) donor DEA NONOate (Item No. 82100).{36864} It has no effect on phosphodiesterases PDE1-9 and PDE11 when used at concentrations up to 3 μM. Riociguat (1 and 10 mg/kg) reduces pulmonary and systemic arterial pressure in a rabbit model of acute pulmonary arterial hypertension (PAH) induced by U-46619 (Item No. 16450). It also inhibits increases in right ventricular systolic pressure, right heart hypertrophy, and pulmonary artery muscularization in hypoxia-induced mouse and monocrotaline-injected rat models of chronic PAH when administered at a dose of 10 mg/kg. Formulations containing riociguat have been used in the treatment of chronic thromboembolic pulmonary hypertension (CTEPH) and PAH.
Brand:CaymanSKU:9000554 - 50 mgAvailable on backorder
RIPGBM is a prodrug form of the pro-apoptotic compound cRIPGBM.{35798} It is converted to cRIPGBM in GBM-1 glioblastoma multiforme (GBM) cancer stem cells (CSCs) but not primary human lung fibroblasts (HLFs). RIPGBM induces apoptosis in GBM CSCs (EC50 = ≤500 nM) and selectively reduces survival of GBM-1 cells (EC50 = 0.22 μM) over human neural stem cells, primary human astrocytes, and primary HLFs (EC50s = 1.7, 2.9, and 3.5 μM, respectively). It reduces tumor growth in a GBM mouse xenograft model using patient-derived GBM-39 cells engineered to express IR fluorescent protein 720 (IRFP720) when administered at a dose of 50 mg/kg twice per day.
Brand:CaymanSKU:27860 - 1 mgAvailable on backorder
RIPGBM is a prodrug form of the pro-apoptotic compound cRIPGBM.{35798} It is converted to cRIPGBM in GBM-1 glioblastoma multiforme (GBM) cancer stem cells (CSCs) but not primary human lung fibroblasts (HLFs). RIPGBM induces apoptosis in GBM CSCs (EC50 = ≤500 nM) and selectively reduces survival of GBM-1 cells (EC50 = 0.22 μM) over human neural stem cells, primary human astrocytes, and primary HLFs (EC50s = 1.7, 2.9, and 3.5 μM, respectively). It reduces tumor growth in a GBM mouse xenograft model using patient-derived GBM-39 cells engineered to express IR fluorescent protein 720 (IRFP720) when administered at a dose of 50 mg/kg twice per day.
Brand:CaymanSKU:27860 - 10 mgAvailable on backorder
RIPGBM is a prodrug form of the pro-apoptotic compound cRIPGBM.{35798} It is converted to cRIPGBM in GBM-1 glioblastoma multiforme (GBM) cancer stem cells (CSCs) but not primary human lung fibroblasts (HLFs). RIPGBM induces apoptosis in GBM CSCs (EC50 = ≤500 nM) and selectively reduces survival of GBM-1 cells (EC50 = 0.22 μM) over human neural stem cells, primary human astrocytes, and primary HLFs (EC50s = 1.7, 2.9, and 3.5 μM, respectively). It reduces tumor growth in a GBM mouse xenograft model using patient-derived GBM-39 cells engineered to express IR fluorescent protein 720 (IRFP720) when administered at a dose of 50 mg/kg twice per day.
Brand:CaymanSKU:27860 - 5 mgAvailable on backorder
Risdiplam is a survival of motor neuron-2 (SMN2) splicing modifier.{50413} It enhances SMN2 splicing (EC1.5x = 40 nM) and increases SMN protein levels (EC1.5x = 163 nM) in cellular assays. Risdiplam (3 mg/kg) increases brain and quadricep muscle SMN protein levels in the adult C/C-allele mouse model of mild spinal muscular atrophy (SMA) and the SMND7 neonate mouse model of severe SMA. It also increases the number of vesicular glutamate transporter 1 (vGLUT1) proprioceptive inputs on motor neurons, the number of L3 to L5 spinal motor neurons, the percentage of fully innervated neuromuscular junctions (NMJs), and the size of the extensor digitorum longus muscles in adult SMND7 mice. Formulations containing risdiplam have been used in the treatment of spinal muscular atrophy.
Brand:CaymanSKU:29028 - 1 mgAvailable on backorder
Risdiplam is a survival of motor neuron-2 (SMN2) splicing modifier.{50413} It enhances SMN2 splicing (EC1.5x = 40 nM) and increases SMN protein levels (EC1.5x = 163 nM) in cellular assays. Risdiplam (3 mg/kg) increases brain and quadricep muscle SMN protein levels in the adult C/C-allele mouse model of mild spinal muscular atrophy (SMA) and the SMND7 neonate mouse model of severe SMA. It also increases the number of vesicular glutamate transporter 1 (vGLUT1) proprioceptive inputs on motor neurons, the number of L3 to L5 spinal motor neurons, the percentage of fully innervated neuromuscular junctions (NMJs), and the size of the extensor digitorum longus muscles in adult SMND7 mice. Formulations containing risdiplam have been used in the treatment of spinal muscular atrophy.
Brand:CaymanSKU:29028 - 10 mgAvailable on backorder
Risdiplam is a survival of motor neuron-2 (SMN2) splicing modifier.{50413} It enhances SMN2 splicing (EC1.5x = 40 nM) and increases SMN protein levels (EC1.5x = 163 nM) in cellular assays. Risdiplam (3 mg/kg) increases brain and quadricep muscle SMN protein levels in the adult C/C-allele mouse model of mild spinal muscular atrophy (SMA) and the SMND7 neonate mouse model of severe SMA. It also increases the number of vesicular glutamate transporter 1 (vGLUT1) proprioceptive inputs on motor neurons, the number of L3 to L5 spinal motor neurons, the percentage of fully innervated neuromuscular junctions (NMJs), and the size of the extensor digitorum longus muscles in adult SMND7 mice. Formulations containing risdiplam have been used in the treatment of spinal muscular atrophy.
Brand:CaymanSKU:29028 - 25 mgAvailable on backorder
Risdiplam is a survival of motor neuron-2 (SMN2) splicing modifier.{50413} It enhances SMN2 splicing (EC1.5x = 40 nM) and increases SMN protein levels (EC1.5x = 163 nM) in cellular assays. Risdiplam (3 mg/kg) increases brain and quadricep muscle SMN protein levels in the adult C/C-allele mouse model of mild spinal muscular atrophy (SMA) and the SMND7 neonate mouse model of severe SMA. It also increases the number of vesicular glutamate transporter 1 (vGLUT1) proprioceptive inputs on motor neurons, the number of L3 to L5 spinal motor neurons, the percentage of fully innervated neuromuscular junctions (NMJs), and the size of the extensor digitorum longus muscles in adult SMND7 mice. Formulations containing risdiplam have been used in the treatment of spinal muscular atrophy.
Brand:CaymanSKU:29028 - 5 mgAvailable on backorder
Risedronate is a heterocyclic orally active aminobisphosphonate.{32680} Like other bisphosphonates, it inhibits bone resorption.{32679,32680} In addition, it has antimalarial activity and inhibits growth of P. falciparum in vitro (IC50 = 20.3 µM) and P. berghei in vivo (25 mg/kg for one week).{35110} It also inhibits protein prenylation by preventing the transfer of a farnesyl pyrophosphate group to parasite proteins. Formulations containing risedronate have been used to reduce fracture risk in both age- and steroid-related osteoporosis.{21586,32679,32680}
Brand:CaymanSKU:20740 -Available on backorder
Risedronate is a heterocyclic orally active aminobisphosphonate.{32680} Like other bisphosphonates, it inhibits bone resorption.{32679,32680} In addition, it has antimalarial activity and inhibits growth of P. falciparum in vitro (IC50 = 20.3 µM) and P. berghei in vivo (25 mg/kg for one week).{35110} It also inhibits protein prenylation by preventing the transfer of a farnesyl pyrophosphate group to parasite proteins. Formulations containing risedronate have been used to reduce fracture risk in both age- and steroid-related osteoporosis.{21586,32679,32680}
Brand:CaymanSKU:20740 -Available on backorder
Risedronate is a heterocyclic orally active aminobisphosphonate.{32680} Like other bisphosphonates, it inhibits bone resorption.{32679,32680} In addition, it has antimalarial activity and inhibits growth of P. falciparum in vitro (IC50 = 20.3 µM) and P. berghei in vivo (25 mg/kg for one week).{35110} It also inhibits protein prenylation by preventing the transfer of a farnesyl pyrophosphate group to parasite proteins. Formulations containing risedronate have been used to reduce fracture risk in both age- and steroid-related osteoporosis.{21586,32679,32680}
Brand:CaymanSKU:20740 -Available on backorder
Risedronate is a heterocyclic orally active aminobisphosphonate.{32680} Like other bisphosphonates, it inhibits bone resorption.{32679,32680} In addition, it has antimalarial activity and inhibits growth of P. falciparum in vitro (IC50 = 20.3 µM) and P. berghei in vivo (25 mg/kg for one week).{35110} It also inhibits protein prenylation by preventing the transfer of a farnesyl pyrophosphate group to parasite proteins. Formulations containing risedronate have been used to reduce fracture risk in both age- and steroid-related osteoporosis.{21586,32679,32680}
Brand:CaymanSKU:20740 -Available on backorder
Risperidone is an atypical antipsychotic that binds to dopamine D2 receptors (Ki = 3 nM) and the serotonin (5-HT) receptor subtype 5-HT2A (Ki = 0.12 nM).{39942,21347} It also binds to dopamine D4, α1- and α2-adrenergic, 5-HT1C, 5-HT1D, and histamine H1 receptors (Kis = 7, 0.81, 7.3, 47, 52, and 2.1 nM, respectively). Risperidone (0.1 mg/kg per day, i.p.) attenuates deficits in prepulse inhibition of the acoustic startle response, but not deficits in social interaction, in a rat neonatal ventral hippocampal lesion model of schizophrenia.{39941} Formulations containing risperidone have been used in the treatment of schizophrenia and bipolar disorder.
Brand:CaymanSKU:- Risperidone is an atypical antipsychotic that binds to dopamine D2 receptors (Ki = 3 nM) and the serotonin (5-HT) receptor subtype 5-HT2A (Ki = 0.12 nM).{39942,21347} It also binds to dopamine D4, α1- and α2-adrenergic, 5-HT1C, 5-HT1D, and histamine H1 receptors (Kis = 7, 0.81, 7.3, 47, 52, and 2.1 nM, respectively). Risperidone (0.1 mg/kg per day, i.p.) attenuates deficits in prepulse inhibition of the acoustic startle response, but not deficits in social interaction, in a rat neonatal ventral hippocampal lesion model of schizophrenia.{39941} Formulations containing risperidone have been used in the treatment of schizophrenia and bipolar disorder.
Brand:CaymanSKU:- Risperidone is an atypical antipsychotic that binds to dopamine D2 receptors (Ki = 3 nM) and the serotonin (5-HT) receptor subtype 5-HT2A (Ki = 0.12 nM).{39942,21347} It also binds to dopamine D4, α1- and α2-adrenergic, 5-HT1C, 5-HT1D, and histamine H1 receptors (Kis = 7, 0.81, 7.3, 47, 52, and 2.1 nM, respectively). Risperidone (0.1 mg/kg per day, i.p.) attenuates deficits in prepulse inhibition of the acoustic startle response, but not deficits in social interaction, in a rat neonatal ventral hippocampal lesion model of schizophrenia.{39941} Formulations containing risperidone have been used in the treatment of schizophrenia and bipolar disorder.
Brand:CaymanSKU:-
Risperidone E-oxime is a potential impurity found in commercial preparations of risperidone.{34751,34752} Risperidone (Item No. 13629) is a longer-acting benzisoxazole derivative used for treating schizophrenia, and also the psychotic, affective, or behavioral symptoms associated with other disorders.{17629,17608} This second-generation antipsychotic was designed to antagonize both D2 and 5-HT2A receptors.{22210,21347} It has little effect on cholinergic and β-adrenergic receptors but does affect α2-adrenergic and histamine H1 receptors.{22210,21347}
Brand:CaymanSKU:22156 -Out of stock
Risperidone E-oxime is a potential impurity found in commercial preparations of risperidone.{34751,34752} Risperidone (Item No. 13629) is a longer-acting benzisoxazole derivative used for treating schizophrenia, and also the psychotic, affective, or behavioral symptoms associated with other disorders.{17629,17608} This second-generation antipsychotic was designed to antagonize both D2 and 5-HT2A receptors.{22210,21347} It has little effect on cholinergic and β-adrenergic receptors but does affect α2-adrenergic and histamine H1 receptors.{22210,21347}
Brand:CaymanSKU:22156 -Out of stock
Risperidone E-oxime is a potential impurity found in commercial preparations of risperidone.{34751,34752} Risperidone (Item No. 13629) is a longer-acting benzisoxazole derivative used for treating schizophrenia, and also the psychotic, affective, or behavioral symptoms associated with other disorders.{17629,17608} This second-generation antipsychotic was designed to antagonize both D2 and 5-HT2A receptors.{22210,21347} It has little effect on cholinergic and β-adrenergic receptors but does affect α2-adrenergic and histamine H1 receptors.{22210,21347}
Brand:CaymanSKU:22156 -Out of stock
Risperidone E-oxime is a potential impurity found in commercial preparations of risperidone.{34751,34752} Risperidone (Item No. 13629) is a longer-acting benzisoxazole derivative used for treating schizophrenia, and also the psychotic, affective, or behavioral symptoms associated with other disorders.{17629,17608} This second-generation antipsychotic was designed to antagonize both D2 and 5-HT2A receptors.{22210,21347} It has little effect on cholinergic and β-adrenergic receptors but does affect α2-adrenergic and histamine H1 receptors.{22210,21347}
Brand:CaymanSKU:22156 -Out of stock
Risperidone-d5 is intended for use as an internal standard for the quantification of risperidone (Item No. 13629) by GC- or LC-MS. Risperidone is an atypical antipsychotic that binds to dopamine D2 receptors (Ki = 3 nM) and the serotonin (5-HT) receptor subtype 5-HT2A (Ki = 0.12 nM).{39942,21347} It also binds to dopamine D4, α1- and α2-adrenergic, 5-HT1C, 5-HT1D, and histamine H1 receptors (Kis = 7, 0.81, 7.3, 47, 52, and 2.1 nM, respectively). Risperidone (0.1 mg/kg per day, i.p.) attenuates deficits in prepulse inhibition of the acoustic startle response, but not deficits in social interaction, in a rat neonatal ventral hippocampal lesion model of schizophrenia.{39941} Formulations containing risperidone have been used in the treatment of schizophrenia and bipolar disorder.
Brand:CaymanSKU:10010570 - 1 mgAvailable on backorder
Risperidone-d5 is intended for use as an internal standard for the quantification of risperidone (Item No. 13629) by GC- or LC-MS. Risperidone is an atypical antipsychotic that binds to dopamine D2 receptors (Ki = 3 nM) and the serotonin (5-HT) receptor subtype 5-HT2A (Ki = 0.12 nM).{39942,21347} It also binds to dopamine D4, α1- and α2-adrenergic, 5-HT1C, 5-HT1D, and histamine H1 receptors (Kis = 7, 0.81, 7.3, 47, 52, and 2.1 nM, respectively). Risperidone (0.1 mg/kg per day, i.p.) attenuates deficits in prepulse inhibition of the acoustic startle response, but not deficits in social interaction, in a rat neonatal ventral hippocampal lesion model of schizophrenia.{39941} Formulations containing risperidone have been used in the treatment of schizophrenia and bipolar disorder.
Brand:CaymanSKU:10010570 - 500 µgAvailable on backorder
Ristocetin A is an antibiotic that was used to treat staphylococcal infections.{32140} However, side effects of ristocetin A included thrombocytopenia and platelet agglutination. Ristocetin A is now used in two assays related to these actions, the ristocetin cofactor assay and the ristocetin-induced platelet aggregation assay. Both assays are used in the diagnosis of von Willebrand disease and other bleeding disorders.{32139,32140}
Brand:CaymanSKU:20601 -Available on backorder
Ristocetin A is an antibiotic that was used to treat staphylococcal infections.{32140} However, side effects of ristocetin A included thrombocytopenia and platelet agglutination. Ristocetin A is now used in two assays related to these actions, the ristocetin cofactor assay and the ristocetin-induced platelet aggregation assay. Both assays are used in the diagnosis of von Willebrand disease and other bleeding disorders.{32139,32140}
Brand:CaymanSKU:20601 -Available on backorder
HDM-2 (human double minute-2; MDM-2 in mouse) is a key negative regulator of p53 that binds to and targets p53 for proteasomal degradation. Overexpression of HDM-2 in some tumors leads to inactivation of p53 thereby allowing tumor cells to escape p53-induced apoptosis.{13684} RITA (reactivation of p53 and induction of tumor cell apoptosis) is a small molecule inhibitor of p53-HDM-2 interaction that can reactivate the tumor suppressor function of wild-type p53.{12386} It binds to p53 with an apparent Kd of 1.5 nM and prevents interaction with HDM-2 resulting in p53 stabilization, accumulation and activation.{12386} RITA potently inhibits the growth of a variety of cancer cell lines in the sub-micromolar range, inducing both DNA-protein and DNA-DNA cross links in human renal cancer cells.{13683} RITA reduced tumor size by 90% at a dose of 10 mg/kg in SCID mice bearing HCT116 tumors, and caused complete regression of A-498 tumor cell xenografts in nude mice at a dose of 45 mg/kg.{12386,13682}
Brand:CaymanSKU:10006426 - 1 mgAvailable on backorder
HDM-2 (human double minute-2; MDM-2 in mouse) is a key negative regulator of p53 that binds to and targets p53 for proteasomal degradation. Overexpression of HDM-2 in some tumors leads to inactivation of p53 thereby allowing tumor cells to escape p53-induced apoptosis.{13684} RITA (reactivation of p53 and induction of tumor cell apoptosis) is a small molecule inhibitor of p53-HDM-2 interaction that can reactivate the tumor suppressor function of wild-type p53.{12386} It binds to p53 with an apparent Kd of 1.5 nM and prevents interaction with HDM-2 resulting in p53 stabilization, accumulation and activation.{12386} RITA potently inhibits the growth of a variety of cancer cell lines in the sub-micromolar range, inducing both DNA-protein and DNA-DNA cross links in human renal cancer cells.{13683} RITA reduced tumor size by 90% at a dose of 10 mg/kg in SCID mice bearing HCT116 tumors, and caused complete regression of A-498 tumor cell xenografts in nude mice at a dose of 45 mg/kg.{12386,13682}
Brand:CaymanSKU:10006426 - 10 mgAvailable on backorder
HDM-2 (human double minute-2; MDM-2 in mouse) is a key negative regulator of p53 that binds to and targets p53 for proteasomal degradation. Overexpression of HDM-2 in some tumors leads to inactivation of p53 thereby allowing tumor cells to escape p53-induced apoptosis.{13684} RITA (reactivation of p53 and induction of tumor cell apoptosis) is a small molecule inhibitor of p53-HDM-2 interaction that can reactivate the tumor suppressor function of wild-type p53.{12386} It binds to p53 with an apparent Kd of 1.5 nM and prevents interaction with HDM-2 resulting in p53 stabilization, accumulation and activation.{12386} RITA potently inhibits the growth of a variety of cancer cell lines in the sub-micromolar range, inducing both DNA-protein and DNA-DNA cross links in human renal cancer cells.{13683} RITA reduced tumor size by 90% at a dose of 10 mg/kg in SCID mice bearing HCT116 tumors, and caused complete regression of A-498 tumor cell xenografts in nude mice at a dose of 45 mg/kg.{12386,13682}
Brand:CaymanSKU:10006426 - 5 mgAvailable on backorder
HDM-2 (human double minute-2; MDM-2 in mouse) is a key negative regulator of p53 that binds to and targets p53 for proteasomal degradation. Overexpression of HDM-2 in some tumors leads to inactivation of p53 thereby allowing tumor cells to escape p53-induced apoptosis.{13684} RITA (reactivation of p53 and induction of tumor cell apoptosis) is a small molecule inhibitor of p53-HDM-2 interaction that can reactivate the tumor suppressor function of wild-type p53.{12386} It binds to p53 with an apparent Kd of 1.5 nM and prevents interaction with HDM-2 resulting in p53 stabilization, accumulation and activation.{12386} RITA potently inhibits the growth of a variety of cancer cell lines in the sub-micromolar range, inducing both DNA-protein and DNA-DNA cross links in human renal cancer cells.{13683} RITA reduced tumor size by 90% at a dose of 10 mg/kg in SCID mice bearing HCT116 tumors, and caused complete regression of A-498 tumor cell xenografts in nude mice at a dose of 45 mg/kg.{12386,13682}
Brand:CaymanSKU:10006426 - 50 mgAvailable on backorder
Ritalinic acid is an inactive, major metabolite of methylphenidate (Item No. 11639), a schedule II drug in the United States commonly used as a psychostimulant for the treatment of attention-deficit hyperactivity disorder, also known as ADHD.{22009} Ritalinic acid is reported to reach plasma concentrations of 1-2 orders of magnitude greater than that of the parent drug and has been monitored in urine to ensure compliance with treatment programs.{25908} This product is intended for forensic and biological research purposes.
Brand:CaymanSKU:- Ritalinic acid is an inactive, major metabolite of methylphenidate (Item No. 11639), a schedule II drug in the United States commonly used as a psychostimulant for the treatment of attention-deficit hyperactivity disorder, also known as ADHD.{22009} Ritalinic acid is reported to reach plasma concentrations of 1-2 orders of magnitude greater than that of the parent drug and has been monitored in urine to ensure compliance with treatment programs.{25908} This product is intended for forensic and biological research purposes.
Brand:CaymanSKU:- Ritalinic acid is an inactive, major metabolite of methylphenidate (Item No. 11639), a schedule II drug in the United States commonly used as a psychostimulant for the treatment of attention-deficit hyperactivity disorder, also known as ADHD.{22009} Ritalinic acid is reported to reach plasma concentrations of 1-2 orders of magnitude greater than that of the parent drug and has been monitored in urine to ensure compliance with treatment programs.{25908} This product is intended for forensic and biological research purposes.
Brand:CaymanSKU:-
Ritanserin is a selective antagonist of the serotonin (5-HT) receptor subtype, 5-HT2A.{39295} In a radioligand binding assay, ritanserin exhibits high selectivity for 5-HT2A over 5-HT1 receptors (IC50s = 0.9 nM and >1000 nM, respectively).{39296} It also demonstrates relatively low affinity for histamine H1, dopamine D2, α1-adrenergic, and α2-adrenergic receptors (39-, 77-, 107-, and 166-fold lower relative to 5-HT2A, respectively). Ritanserin (2.5 mg/kg) is long-acting, occupying >70% of 5-HT2A sites up to 48 hours following subcutaneous administration to rats and guinea pigs. In vivo, ritanserin (10 mg/kg) blocks 5-hydroxy tryptophan-induced head twitches in rats.{39297}
Brand:CaymanSKU:21374 -Out of stock
Ritanserin is a selective antagonist of the serotonin (5-HT) receptor subtype, 5-HT2A.{39295} In a radioligand binding assay, ritanserin exhibits high selectivity for 5-HT2A over 5-HT1 receptors (IC50s = 0.9 nM and >1000 nM, respectively).{39296} It also demonstrates relatively low affinity for histamine H1, dopamine D2, α1-adrenergic, and α2-adrenergic receptors (39-, 77-, 107-, and 166-fold lower relative to 5-HT2A, respectively). Ritanserin (2.5 mg/kg) is long-acting, occupying >70% of 5-HT2A sites up to 48 hours following subcutaneous administration to rats and guinea pigs. In vivo, ritanserin (10 mg/kg) blocks 5-hydroxy tryptophan-induced head twitches in rats.{39297}
Brand:CaymanSKU:21374 -Out of stock
Ritanserin is a selective antagonist of the serotonin (5-HT) receptor subtype, 5-HT2A.{39295} In a radioligand binding assay, ritanserin exhibits high selectivity for 5-HT2A over 5-HT1 receptors (IC50s = 0.9 nM and >1000 nM, respectively).{39296} It also demonstrates relatively low affinity for histamine H1, dopamine D2, α1-adrenergic, and α2-adrenergic receptors (39-, 77-, 107-, and 166-fold lower relative to 5-HT2A, respectively). Ritanserin (2.5 mg/kg) is long-acting, occupying >70% of 5-HT2A sites up to 48 hours following subcutaneous administration to rats and guinea pigs. In vivo, ritanserin (10 mg/kg) blocks 5-hydroxy tryptophan-induced head twitches in rats.{39297}
Brand:CaymanSKU:21374 -Out of stock